A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

Summary

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with relapsed or refractory hematologic malignancies, regardless of gender, aged between 18(inclusive) and 70 years . Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

Timeline

Start

2025-10

Primary completion

2028-01

Completion

2028-04

Drugs

Indications